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Purpose: Combination therapy of α-blockers and 5α-reductase inhibitors (5-ARIs) is 
widely used for the treatment of benign prostatic hyperplasia (BPH). We aimed to study 
the effect on prostate volume and symptoms of shifting to monotherapy in patients who 
previously received a combination therapy. 
Materials and Methods: A prospective study was conducted of 60 patients who were 
diagnosed with BPH. Patients were aged 45 years or older and had a prostate volume 
of 30 cc or more, International Prostate Symptom Score (IPSS) of 12 or above, maximal 
flow rate (Qmax) of 15 ml/s or less, and prostate-specific antigen (PSA) level of less than 
10 ng/ml. The patients initially received a combination therapy of doxazosin 4 mg/day 
and finasteride 5 mg/day for 3 months and were then randomly assigned to receive mon-
otherapy for 3 months. The factors were then compared.
Results: A total of 30 patients were assigned to doxazosin (group 1) and 30 to finasteride 
(group 2) after the combination therapy. The percentage changes in prostate volume, 
IPSS, and Qmax during the period from post-combination therapy to post-monotherapy 
were not significantly different between the two groups (p=0.052, 0.908, 0.081), where-
as PSA significantly decreased in group 2 (p＜0.001). IPSS was not significantly differ-
ent at post-combination therapy and at post-monotherapy in both groups (p=0.858, 
0.071). The prostate volume significantly increased from 40.97 cc at post-combination 
therapy to 44.29 cc at post-monotherapy in group 1 (p=0.001) and insignificantly in-
creased from 38.32 cc to 38.61 cc in group 2 (p=0.696). 
Conclusions: Although the duration of drug administration was short in this study, 
5-ARI monotherapy could maintain the alleviated symptoms and reduce the risk of 
acute urinary retention and surgery due to prostate regrowth in BPH patients whose 
symptoms improved with combination therapy.
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Benign prostatic hyperplasia (BPH) is a common disease 
process that affects an increasing percentage of men as 
they age. It is prevalent in the 40- to 79-year-old age group, 
with incidences ranging from 14% to 56% in different coun-
tries [1]. BPH-induced lower urinary tract symptoms 
(LUTS) are bothersome to most patients and substantially 
impact their quality of life. In addition, BPH can be a pro-
gressive disease and may lead to acute urinary retention 
(AUR) and BPH-related surgery [2]. The main goals of ther-
apy for BPH are to improve LUTS and enhance quality of Korean J Urol 2011;52:681-686
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life. Other goals include slowing disease progression, pre-
venting complications (e.g., AUR), and delaying the need 
for surgery [3,4]. Until recently, the most widely recognized 
standard treatment for BPH was transurethral resection 
of the prostate (TURP). Since Caine et al first reported on 
the possibility of drug therapy, however, many effective 
drugs have been developed, and in recent years, drug ther-
apy has been used as a mainstream modality in most pa-
tients [5,6]. Alpha-adrenergic receptor blockers (α-block-
ers) and 5α-reductase inhibitors (5-ARIs) have been main-
ly used for the medical treatment of BPH. α-blockers (e.g., 
doxazosin, terazosin, tamsulosin) decrease smooth muscle 
tone in the prostate gland, prostatic capsule, prostatic ure-
thra, and bladder [7]. In contrast, 5-ARIs (e.g., finasteride, 
dutasteride) reduce the prostate volume by inhibiting the 
production of dehydrotestosterone, which is the primary 
androgen driving both normal prostate development and 
the hyperplasia of the prostatic transitional zone that is re-
sponsible for the development of BPH [8]. The Medical 
Therapy of Prostatic Symptoms Study (MTOPS) reported 
that the risk of AUR in patients with BPH decreased con-
siderably with finasteride monotherapy or with the combi-
nation of doxazosin and finasteride compared with dox-
azosin monotherapy. The study added that α-blocker mon-
otherapy could only delay the onset of complications, such 
as AUR, whereas combination therapy of α-blockers and 
5-ARIs could reduce the risk of AUR and surgical treatment 
[9]. Since Glassmann et al first suggested that combination 
therapy of terazosin and finasteride could enhance the 
treatment effect for BPH by observing that, compared with 
terazosin monotherapy, the combination therapy sig-
nificantly increased the apoptotic index of prostatic cells, 
this combination therapy has been widely used [10]. 
In South Korea, many studies have reported on the risk 
factors of AUR and prostatic surgery and the degree of im-
provement in LUTS and maximal flow rate (Qmax) in pa-
tients with BPH who receive combination therapy of 
α-blockers and 5-ARIs. However, the effect on the prostate 
of shifting from combination therapy to monotherapy of 
α-blockers or 5-ARIs in patients with BPH is not known. 
BPH is common among older males, and most of these pa-
tients have underlying comorbidities such as hypertension 
and diabetes. Thus, these patients feel burdened by the 
number of drugs they have to take. By applying mono-
therapy after combination therapy, the cost and incon-
venience of a second medication, as well as the side effects 
of combination therapy, could be reduced. Therefore, we 
conducted a prospective, randomized, and comparative 
single-center trial to investigate the effect on the prostate 
volume and symptoms of shifting from combination ther-
apy of α-blockers and 5-ARIs to monotherapy of either 
α-blockers or 5-ARIs. 
MATERIALS AND METHODS
A prospective study was conducted on 60 patients who were 
diagnosed with BPH from February 2010 to February 2011 
at the Department of Urology, Sahmyook Medical Center. 
Patients were aged 45 years or older and had a prostate vol-
ume of 30 cc or more based on transrectal ultrasonography 
(TRUS), an International Prostate Symptom Score (IPSS) 
of 12 or above, Qmax of 15 ml/s or less, and prostate-specific 
antigen (PSA) level of less than 10 ng/ml. Patients who had 
a PSA level of 4-10 ng/ml underwent TRUS-guided prostate 
needle biopsy (10- or 12-core), and patients who were diag-
nosed with BPH were included in the study. Patients who 
had a history of TURP, had prostatitis or recurrent urinary 
tract infection, had a PSA level of 10 ng/ml or more, or were 
taking α-blockers or other drugs such as 5-ARIs that are 
known to exert an influence on the PSA level were excluded 
from the study. 
The subjects had their prostate volume, PSA, IPSS, and 
Qmax measured at the time of their presentation to the 
hospital. The prostate volume was calculated by measur-
ing the height, width, and length by using TRUS and by put-
ting these values into the ellipsoid formula of 3.14/6x 
(height)x(width)x(length). TRUS was performed by one ur-
ologist who was blinded to patient assignment. PSA was 
measured by enzyme immunoassay, and it was measured 
before the TRUS to minimize interference. Uroflowmetry 
was performed with the patient in a standing position, and 
the voided volume and Qmax were recorded continuously 
during micturition with a minimum voided volume ≥125 
ml.
The subjects received combination therapy of doxazosin 
4 mg/day and finasteride 5 mg/day as an initial drug treat-
ment for 3 months and then underwent measurements of 
prostate volume, PSA, IPSS, and Qmax. After the 3-month 
combination therapy, the subjects were randomly assigned 
to receive monotherapy of either doxazosin (group 1) or fi-
nasteride (group 2) for 3 months. The prostate volume, 
PSA, IPSS, and Qmax were then measured. All patients re-
ceived a combination of 2 tablets (doxazosin with finas-
teride) for 3 months, followed by 3 months of monotherapy 
of 1 tablet (doxazosin or finasteride) without use of a 
placebo. All patients were blinded to drug assignment.
The percentage changes in each factor during the period 
from post-combination therapy to post-monotherapy of 
each group were compared and analyzed. The values of 
each factor measured at post-monotherapy were sub-
tracted from the values of each factor measured at 
post-combination therapy. The remainder was divided by 
the values measured at post-combination therapy and was 
used as the percentage of change. 
For statistical analysis, a Student’s t-test was performed 
by using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). 
Statistical significance was set at a p-value＜0.05.
RESULTS
The mean age among the 60 subjects was 68.2 years. Before 
the treatment, the mean prostate volume was 48.6 cc; mean 
PSA, 1.88 ng/ml; mean IPSS, 16.87; and mean Qmax, 11.53 
ml/s. Of the entire 60 subjects, 30 (group 1) received dox-Korean J Urol 2011;52:681-686
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TABLE 2. Comparison of changes in prostate volume, PSA, IPSS, and Qmax according to study duration between the two groups 
Prostate volume (cc) PSA (ng/ml)
Group 1  Group 2 p-value Group 1  Group 2 p-value
Duration (wk)             0 50.27±20.23       46.89±13.75 0.453     2.03±1.80    1.72±1.57 0.484
                                  12 40.97±14.03       38.32±12.43 0.442     1.09±0.82    1.23±1.37 0.631
                                  24 44.29±16.73       38.61±11.00 0.126     1.63±1.18    0.87±0.78 0.004
Change from 0 to 12 (%) −15.89±14.01 −18.26±9.81 0.451 −36.48±38.39 −23.35±34.99 0.172
Change from 12 to 24 (%) 7.69±12.31       1.98±9.84 0.052     86.04±81.67   −36.35±146.40 ＜0.001
IPSS Qmax (ml/s)
Group 1  Group 2 p-value Group 1  Group 2 p-value
Duration (wk)             0  16.70±4.78  17.03±6.50 0.822 11.58±2.15  11.47±3.02 0.879
                                  12  11.43±4.95  13.10±6.46 0.267 15.01±3.32  16.88±6.01 0.143
                                  24  11.57±3.96  14.00±6.28 0.079 14.15±4.21  14.66±6.34 0.715
Change from 0 to 12 (%)  −29.88±26.09 −25.03±15.73 0.387   33.78±34.65    59.54±71.03 0.081
Change from 12 to 24 (%)     13.03±46.21    11.94±22.82 0.908 −3.55±25.62 −12.08±25.37 0.200
PSA: prostate-specific antigen, IPSS: International Prostate Symptom Score, Qmax: maximal flow rate
TABLE 1. Patient baseline characteristics in group 1 and group 2
Total Group 1 Group 2 p-value
No. of patients 60 30 30
Age (yr) 68.20±8.18 67.57±8.50 68.83±7.95 0.553
Prostate volume (cc)   48.58±17.23   50.27±20.23   46.89±13.75 0.453
PSA (ng/ml)   1.88±1.68   2.03±1.80   1.72±1.57 0.484
IPSS 16.87±5.66 16.70±4.78 17.03±6.50 0.822
Qmax (ml/s) 11.53±2.60 11.58±2.15 11.48±3.02 0.879
PSA: prostate-specific antigen, IPSS: International Prostate Symptom Score, Qmax: maximal flow rate
azosin monotherapy and 30 (group 2) received finasteride 
monotherapy after the combination therapy of doxazosin 
4 mg/day and finasteride 5 mg/day. Age (67.57 vs 68.83 
years, p=0.533), prostate volume (50.27 vs 46.89 cc, 
p=0.453), PSA (2.03 vs 1.72 ng/ml, p=0.484), IPSS (16.70 
vs 17.03, p=0.822), and Qmax (11.58 vs 11.48 ml/s, p=0.879) 
measured before combination therapy were not sig-
nificantly different between the two groups (Table 1). 
For group 1, after 3 months of combination therapy, the 
mean prostate volume significantly decreased from 50.27 
cc to 40.97 cc, mean IPSS from 16.7 to 11.43, and mean PSA 
from 2.03 ng/ml to 1.09 ng/ml, whereas mean Qmax sig-
nificantly increased from 11.58 ml/s to 15.01 ml/s (p
＜0.001, respectively). For group 2, after 3 months of combi-
nation therapy, the mean prostate volume significantly de-
creased from 46.89 cc to 38.22 cc, mean IPSS from 17.03 to 
13.10, and mean PSA from 1.72 ng/ml to 1.23 ng/ml (p
＜0.001, p＜0.001, p=0.015, respectively), whereas mean 
Qmax significantly increased from 11.47 ml/s to 16.88 ml/s 
(p＜0.001). The percentage change in each factor after 3 
months of combination therapy was not significantly dif-
ferent between the two groups: prostate volume (−15.89 
vs −18.26%, p=0.451), IPSS (−29.88 vs −25.03%, p= 
0.387), Qmax (33.78 vs 59.54%, p=0.081), and PSA (−36.48 
vs −23.35%, p=0.172) (Table 2).
After 3 months of monotherapy of either doxazosin or fi-
nasteride administered after 3 months of combination 
therapy, for group 1, the mean prostate volume sig-
nificantly increased from 40.97 cc to 44.29 cc; mean PSA 
increased from 1.09 ng/ml to 1.63 ng/ml (p＜0.001 and p
＜0.001, respectively); mean IPSS increased from 11.43 to 
11.57 (p=0.858); and Qmax decreased from 15.01 ml/s to 
14.15 ml/s, although not significantly (p=0.131). For group 
2, the mean prostate volume increased from 38.32 cc to 
38.61 cc and mean IPSS increased from 13.1 to 14.00; mean 
PSA decreased from 1.23 ng/ml to 0.87 ng/ml, although not 
significantly (p=0.696, p=0.071, and p=0.051, respective-
ly). The mean Qmax significantly decreased from 16.88 
ml/s to 14.66 ml/s (p=0.014). The percentage change in 
prostate volume (+7.69% vs. +1.98%, p=0.052), IPSS 
(+13.03% vs. +11.94%, p=0.908), and Qmax (−3.55% vs. 
−12.08%, p= 0.081) during the period from post-combina-
tion therapy to post-monotherapy of either doxazosin or fi-
nasteride was not significantly different between the two 
groups, whereas PSA significantly decreased in group 2 
(+86.04% vs. −36.35%, p＜0.001)(Table 2). 
After 6 months of treatment (combination therapy for 3 
months and monotherapy for 3 months), the prostate vol-
ume was 91.51% of the baseline volume in group 1 and 
83.12% in group 2. The rates were significantly different Korean J Urol 2011;52:681-686
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between the two groups (p=0.029)(Table 2).
Among the 60 subjects, AUR or prostatic surgery did not 
occur during the 6 months of treatment. 
DISCUSSION
BPH is a long-term, progressive disease that considerably 
impacts the quality of life of patients by causing LUTS. As 
the disorder advances, it can lead to a worsening of symp-
toms and an increased risk of serious outcomes, such as 
AUR and disease-related surgery [11]. Recently, the atten-
tion related to drug treatment for BPH has focused on re-
ducing LUTS as well as preventing the progression of BPH 
by reducing AUR or risk of surgery related to BPH. Because 
combination therapy of α-blockers and 5-ARIs is more ef-
fective than either drug alone in reducing the risk of BPH 
progression and improving symptoms, this combination 
therapy is commonly used for the treatment of BPH. With 
combination therapy, the α-blocker relieves symptoms un-
til the 5-ARIs have time to resolve the obstruction and im-
prove the symptoms. Once the prostate volume is de-
creased and the LUTS are improved by the combination 
therapy, monotherapy might be possible with either an 
α-blocker or a 5-ARI.
Gormley et al reported that significant reductions in 
prostate volume occurred within 3 months of therapy with 
finasteride [12]. In the present study, after 3 months of 
combination therapy, the patients received 3 months of 
monotherapy. After combination therapy for 3 months, we 
observed that prostate volume decreased by 15.89% and by 
18.26% in groups 1 and 2, respectively (Table 2).
Stoner reported that the prostate volume returned to 
near baseline values at 12 weeks after the finasteride was 
discontinued [8]. Jeong et al suggested that as the prostate 
regrows, after discontinuing the 5-ARIs, the LUTS sig-
nificantly worsened compared with the values after 1 year 
of combination therapy despite maintenance with the 
α-blocker [13]. The results of that study showed that pros-
tate shrinkage in the dutasteride-treated group was 73.9% 
of the baseline level and was 75.5% in the finas-
teride-treated group at 12 months after combination 
therapy. At 1 year after the 5-ARIs had been withdrawn, 
the mean percentage of prostate regrowth was 20.7% and 
18.6% in the finasteride-treated group and the dutas-
teride-treated group, respectively. Thus, the prostate vol-
ume in the finasteride-treated group had increased to ≤
91.1% of the baseline value at 1 year after cessation of the 
drug. The prostate regrowth in the dutasteride-treated 
group had reached ≤87.6% of the baseline volume [13]. 
In the present study, after 3 months of combination ther-
apy, the prostate volume was 84.1% of the baseline volume 
in group 1 and 81.7% in group 2. In group 1, in which only 
doxazosin was administered and finasteride was dis-
continued after 3 months of combination therapy, the mean 
prostate volume significantly increased by 7.69% from 
40.97 cc to 44.29 cc, indicating prostate regrowth (p
＜0.001). In group 2, in which only finasteride was ad-
ministered and doxazosin was discontinued after 3 months 
of combination therapy, the mean prostate volume in-
creased, although not significantly, by 1.98% from 38.32 cc 
to 38.61 cc without considerable regrowth (p=0.696). After 
combination therapy and monotherapy for 6 months, the 
percentage change in prostate volume was significantly 
different between the two groups (p=0.029). In group 1, 
prostate volume was 91.5% of baseline volume, whereas it 
was 83.1% in group 2 (Table 2). It is believed that compared 
with α-blocker monotherapy, monotherapy using 5-ARIs 
after combination therapy could reduce the risk of AUR and 
surgery due to prostate regrowth. 
The mechanism of the prostate regrowth phenomenon 
after 5-ARI withdrawal is not fully understood, because the 
etiologies of prostate enlargement are multifactorial and 
complex. Because the development of BPH is an an-
drogen-dependent process, however, it is possible that the 
prolonged pharmacologic inhibition of 5α-reductase, by 
the 5-ARIs, results in an overactivity of, or increased sensi-
tivity to, dehydrotestosterone. An alternative mechanism 
might be that androgen receptors become more sensitive 
or upregulated during treatment with 5-ARIs. These ex-
planations could partly account for prostate gland re-
growth after discontinuing the chronic inhibition of the 
5α-reductase [13].
5-ARIs, when used alone, have an onset of action of 3 to 
6 months compared with 2 to 4 weeks for α-blockers [14]. 
Long-term therapy with a 5-ARI is maintained to reduce 
prostate volume and positively impact the long-term risk 
of BPH progression, reducing the risk of AUR and BPH-re-
lated surgery. Combination therapy can offer rapid relief 
of symptoms associated with α-blockers and the long-term 
benefits of 5-ARIs. The α-blocker would alleviate the symp-
toms until the 5-ARIs could reduce the obstruction, im-
prove the symptoms, and decrease the risk of AUR and the 
need for outlet-reducing surgery [15]. Thus, it may not be 
necessary to continue the α-blocker therapy. Barkin et al 
reported that in men with BPH initially treated with a com-
bination of dutasteride and tamsulosin, the α-blocker can 
be withdrawn in the majority of patients (77%) after 6 
months [16]. Baldwin et al likewise observed that α-blocker 
therapy could be withdrawn in the majority of male pa-
tients (84%) after 9 or 12 months of combination therapy 
[17]. Nickel et al reported that finasteride monotherapy af-
ter combination therapy could sufficiently control the 
LUTS associated with BPH. Nickel et al also reported that 
the IPSS scores after 3 months of finasteride monotherapy, 
following a 9-month course of combination therapy with fi-
nasteride and an α-blocker, were within the criteria for 
equivalence to those after 9 months of combination therapy 
[18]. 
After 3 months of combination therapy, we observed that 
the IPSS significantly decreased by 5.3 (−29.88%) and 3.9 
(−25.03%) in groups 1 and 2, respectively (p＜0.001). By 
contrast, Qmax significantly increased by 3.4 ml/s 
(33.78%) and 5.41 ml/s (59.54%) in groups 1 and 2, re-
spectively (p＜0.001). From post-combination therapy for Korean J Urol 2011;52:681-686
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3 months to post-monotherapy of either doxazosin or finas-
teride for 3 months, IPSS increased by 0.14 (13.03%) and 
0.9 (11.94%), in groups 1 and 2, respectively. Thus, the IPSS 
of post-monotherapy was not significantly different from 
that of post-combination therapy in either group (p=0.858 
and p=0.071, respectively), and the percentage change was 
not significantly different between the two groups (p= 
0.131). In group 1, Qmax decreased by 0.86 ml/s (−3.55%); 
thus, no change was observed (p=0.131). By contrast, in 
group 2, it significantly decreased by 2.22 ml/s (12.08%) (p= 
0.014). However, there was no significant difference in the 
percentage change between the two groups (p=0.200) 
(Table 2). When only 5-ARIs were used after the combina-
tion therapy, Qmax increased more compared with when 
only α-blockers were used. However, there was no consid-
erable difference in the percentage change between the two 
groups, and the increase was not sufficient to exert an influ-
ence on IPSS. This suggests that shifting from combination 
therapy to monotherapy by using α-blockers or 5-ARIs 
could help to maintain the improved symptoms that were 
achieved by the combination therapy. 
Brawer et al reported that after 54 weeks of combination 
therapy of α-blockers and 5-ARIs, PSA decreased by 60% 
or more in 31.4% of the patients, by 40% to 60% in 30.3%, 
by 20% to 39% in 16.8%, and by 0% to 20% in 12.8%, whereas 
it increased in 8.9% of the patients. However, Brawer et al 
reported that when the patients were monitored during 52 
weeks of terazosin therapy, PSA was not affected at all [19]. 
Soh et al reported that α-blocker monotherapy had almost 
no influence on PSA even with long-term administration, 
and Roehrborn et al also reported that α-blockers (terazo-
sin) did not influence PSA in BPH patients with LUTS [20, 
21]. Guess et al described that after 1 year of finasteride 
monotherapy in BPH patients, PSA decreased by about 
50% [22]. 
The result of our study showed that after 3 months of 
combination therapy, PSA decreased by 36.48% and 
23.35% in groups 1 and 2, respectively. In group 1, which 
received doxazosin monotherapy after combination ther-
apy, PSA increased significantly by 86.04% (p=0.002). In 
group 2, which received dutasteride monotherapy after 
combination therapy, PSA decreased by 36.35% (p=0.051) 
(Table 2). This indicates that α-blocker monotherapy after 
combination therapy with discontinuation of 5-ARIs could 
result in prostate volume regrowth as well as an increase 
in the PSA level. 
Although α-blocker therapy is associated with a rapid on-
set of symptom relief and improvement in Qmax in men 
with BPH, it lacks the effect of the 5-ARIs on prostate 
volume. Its inability to reduce prostate volume may also ac-
count for the finding that rates of treatment failure with 
α-blockers are higher in men with larger (＞40 cc) versus 
smaller prostate volumes [23,24]. Thus, in BPH patients 
with larger prostate volume, α-blocker monotherapy after 
combination therapy could not reduce the risk of AUR and 
prostatic surgery resulting in prostate regrowth, com-
pared with 5-ARI monotherapy. 
In this study, although α-blocker monotherapy after 
combination therapy could maintain the improved symp-
toms achieved by the combination therapy, regrowth of 
prostate volume was observed. Thus, this indicates that in 
BPH patients with moderate to severe symptoms, who 
have prostate volume of 30 cc or more according to TRUS, 
IPSS of 12 or more, and Qmax of 15 ml/s or less, α-blocker 
monotherapy after combination therapy is not expected to 
have an adverse impact on the improved symptoms from 
a short-term point of view, but is likely to cause adverse 
events such as aggravation of symptoms and AUR due to 
prostate regrowth from a long-term point of view. 
In BPH patients with moderate to severe symptoms, 
5-ARI monotherapy maintained the improved symptoms 
achieved by combination therapy, and no prostate re-
growth was observed. In addition, the reduced PSA level 
achieved by the combination therapy was also maintained. 
Thus, 5-ARI monotherapy with discontinuation of α-block-
ers after combination therapy is not expected to have an 
adverse impact on the symptoms of patients. It is also ex-
pected to reduce the risk of AUR and surgery due to prostate 
regrowth. 
The main limitation of this study was the short duration 
of the combination therapy and the short follow-up period. 
Short-term trials comparing combination therapy with 
α-blockers alone have found no significant benefits. The VA 
Cooperative Study and the Prospective European Doxazo-
sion and Combination Theraphy trial demonstrated no 
benefit in symptoms or urinary flow rate with combination 
therapy versus α-blocker monotherapy after 1 year. 
Finasteride was shown to be no better than placebo for 
these outcomes [25,26]. However, the MTOPS authors con-
cluded that long-term combination therapy significantly 
reduces overall clinical progression of BPH compared with 
monotherapy using doxazosin or finasteride. Combination 
therapy and finasteride alone reduced the long-term risk 
of AUR and the need for invasive therapy [9]. Thus, combi-
nation therapy and finasteride alone require long-term 
use. Several studies have demonstrated that the α-blocker 
can be withdrawn after an interval of combination therapy, 
after which symptom control is maintained with a 5-ARI 
alone [16-18]. The optimal duration of combination ther-
apy seems to be around 9 months, because 84% of the men 
were able to discontinue α-blockers after 9 months with no 
increase in symptoms [27]. Because the follow-up period 
was short in this study, studies are required to investigate 
the possible impact of long-term administration on the 
symptoms and whether 5-ARIs could really reduce the risk 
of acute urinary retention and prostatic surgery. In addi-
tion, because this study is based on a single-center analysis 
of data, the number of patients was small and the variety 
of patients was low. Multi-center studies with more diverse 
patients are thus required. 
CONCLUSIONS
In this study, in BPH patients with moderate to severe Korean J Urol 2011;52:681-686
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LUTS who had prostate volumes of 30 cc or more on the ba-
sis of TRUS performed by one urologist and an IPSS of 12 
or above, 5-ARI monotherapy maintained the improved 
IPSS and Qmax without prostate regrowth and with a re-
duction in the PSA level after combination therapy with an 
α-blocker and 5-ARI. Although the duration of drug admin-
istration was short in this study, our results suggest that 
in BPH patients whose symptoms improved with combina-
tion therapy, 5-ARI monotherapy could maintain the alle-
viated symptoms and reduce the risk of AUR and prostatic 
surgery due to prostate regrowth. 
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